Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2018

View Archived Issues

Phase IIb trial of Mtb72F-AS02A vaccine shows 54% protection against active pulmonary tuberculosis

Let sleeping cells lie: Neutrophil extracellular traps untrap dormant tumor cells

C1QBP found to predict survival in mesothelioma patients under chemotherapy

Immunologically humanized mouse model better captures immune responses during hepatitis B infection

Phase II results presented for ustekinumab in patients with active systemic lupus erythematosus

PFKFB3 inhibitor selectively radiosensitizes cancer cells, blocking homologous recombination

Fluorescent virus-guided cytology detects active cancer cells in peritoneally disseminated GC

Nimbus Lakshmi patents TYK2 inhibitors

In situ TLR9-agonist vaccine plus low dose radiation induces systemic responses in indolent lymphoma

Takeda Pharmaceutical divulges new orexin OX2 receptor agonists

Janssen identifies new BACE inhibitors

Acquired resistance to enasidenib is mediated by a second-site mutation in the IDH2 dimer-interface

U.S. researchers divulge MALT1 inhibitors

Celyad enters agreement to use Horizon Discovery's shRNA technology

New triple-combination study explores plinabulin, nivolumab and ipilimumab in SCLC

Celgene opens recruitment in phase III study of JCAR-017 for second-line NHL

First patient enrolled in phase III study of glepaglutide for short bowel syndrome

Novartis initiates first-in-human study of CPK-850 for retinitis pigmentosa

Phase II data presented from NADIM study of neoadjuvant chemotherapy and immunotherapy in NSCLC

FDA approves Hemlibra for prophylaxis in hemophilia A without factor VIII inhibitors

Alnylam reports phase I/II data on lumasiran in PH1, initiates phase III trial

NIH research grant to support phase II program with PTI-125 in Alzheimer's

Oncology Venture cleared to include prostate cancer patients in phase II study of LiPlaCis

Oramed initiates pilot study of ORMD-0801 in NASH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...